This Phase 1 open label study is being conducted to characterize the pharmacokinetic (PK) and safety profiles of Chiglitazar with Empagliflozin,Atorvastatin and Valsartan in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
48
Zhongshan hospital
Shanghai, China
Cmax
Maximum plasma concentration
Time frame: up to 72 hours
AUC0-t and AUC0-inf
Area under of the curve (AUC0-t and AUC0-inf)
Time frame: up to 72 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Valsartan 160mg